Ease Labs International

What Ease Labs International does

Ease Labs International (operating commercially as Ease Labs Pharma) is a Brazilian pharmaceutical company headquartered in Belo Horizonte that develops, produces, and distributes prescription Cannabis-based medicines. Founded in 2018, the company positions itself as the first Brazilian pharmaceutical industry specialized exclusively in Cannabis products and operates a vertically integrated production model that controls all stages from plant cultivation through final product delivery. Its commercial focus is physicians authorized to prescribe under ANVISA's RDC 327/2019 framework and patients with neurological and psychiatric conditions—including epilepsy, autism spectrum disorder, chronic pain, fibromyalgia, anxiety, and insomnia—particularly those with treatment-resistant indications where conventional therapies have proven insufficient. The company employs 101–250 people and has expanded through two adjacent entities: Semeya (focused on Cannabis and broader botanical active ingredients R&D) and Ease Labs Colombia (targeting the Colombian market).

The company's commercial portfolio centers on two core phytopharmaceutical products derived from Cannabis sativa L.: Canabidiol (CBD), an isolated CBD formulation with concentrations exceeding 99% purity and no detectable THC produced via crystallization processes; and Extrato de Cannabis, a full-spectrum extract containing multiple cannabinoids (CBD, THC, CBG, CBC), terpenes, and flavonoids. Both products are manufactured at the company's ANVISA-certified facility under Certificação de Boas Práticas de Fabricação (CBPF) and require a Type B (blue) medical prescription. Supporting the portfolio are a Medical Area portal for physician education, a Pharmacist Portal for dispensing guidance, and the PACCE Cannabinoid Knowledge Acceleration Program—a research initiative developed in collaboration with Brazilian universities (USP, UFMG) and institutions (ANVISA, CERTBIO).

The business operates a sales-led, prescription-only go-to-market: products are dispensed exclusively through licensed non-compounding pharmacies and drugstores nationwide, with no direct-to-consumer or online channels. Distribution is reinforced by a pharmacy partner program that allows retailers to apply as authorized dispensers. Leadership comprises co-CEOs Gustavo Palhares and Guilherme Franco, a Marketing Director (Sérgio Andrade) with prior experience at Teva, Janssen, and Novartis, and consulting advisors from Alvarez & Marsal's health practice. The company has raised approximately R$ 27 million in disclosed capital through a 2022 seed-equity round led by MadFish and a 2023 venture debt facility from Itaú, with website-reported additional rounds in 2024 and 2025 from Airborne Ventures, L5 Capital, and Itaú BBA International plc suggesting continued scaling capital.

Name

Ease Labs International

Website

https://easelabspharma.com.br

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Ease Labs International is a Brazilian pharmaceutical company headquartered in Belo Horizonte that develops, produces, and distributes ANVISA-registered prescription Cannabis-based medicines—isolated CBD and full-spectrum Cannabis extract—through licensed pharmacies nationwide for patients with neurological and psychiatric conditions.

Ownership category

akta.pro rank

Product category

Medical Cannabis Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Medical and Diagnostic Laboratories (62151)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

akta.pro secondary industry

Medical Cannabis Dispensaries (CRANAFAB)

Keywords

• Pharmaceutical cannabis products
• Cannabidiol CBD medicines
• Medical cannabis manufacturing
• Phytopharmaceutical cannabis extracts
• Cannabis based medicines

Headquarters

HQ city

Belo Horizonte

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Cannabis-based Pharmaceutical Products: Sale of prescription-only Cannabis-derived products including Cannabidiol (CBD) isolate and Cannabis Extract through licensed pharmacies. Products are regulated under ANVISA's RDC 327/2019 and require medical prescription.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Ease Labs International is a Brazilian pharmaceutical group that develops, manufactures, and distributes prescription-only Cannabis-based phytopharmaceutical products — Canabidiol (CBD) isolate and full-spectrum Cannabis Extract — regulated by ANVISA under RDC 327/2019. Products are sold exclusively through licensed pharmacies and drugstores across Brazil upon presentation of a Type B (blue) medical prescription, supported by vertically integrated production from plant cultivation to final delivery.

Product overview

Ease Labs Pharma is the first Brazilian pharmaceutical industry specialized in Cannabis products, operating as a unified product portfolio centered on two core pharmaceutical offerings: Canabidiol (CBD) isolated product and Extrato de Cannabis full-spectrum extract. Both products are phytopharmaceuticals derived from Cannabis sativa L. regulated under RDC 327/2019 and require medical prescription. The portfolio is supported by the Área Médica (Medical Area) portal for physician education, the Área do Farmacêutico (Pharmacist Portal) for dispensing support, and the PACCE research acceleration program. The company operates with verticalized production controlling all stages from plant cultivation to final product delivery, with GMP certification from ANVISA.

Differentiator

Problem solved

Functional benefit

Products and services

• Canabidiol (CBD) Phytopharmaceutical product containing isolated Cannabidiol (CBD) derived from Cannabis sativa L. with no detectable THC. Produced at 100mg/mL concentration exceeding 99% purity, sold as a prescription-only medication under ANVISA RDC 327/2019 requiring a Type B (blue) medical prescription. Targeted at patients with treatment-resistant neurological and psychiatric conditions.
• Extrato de Cannabis Full-spectrum Cannabis extract derived from Cannabis sativa L. containing multiple cannabinoids (CBD, THC, CBG, CBC), terpenes, and flavonoids. Provides phytocomplex formulation as opposed to isolated CBD. Sold as a prescription-only medication under ANVISA RDC 327/2019 for patients requiring a full-spectrum cannabinoid therapeutic option.

Quantifiable outcome

• Safety and pharmacological toxicity tests completed and attested
• +2 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Mais AlíviominorGTM or Marketing PartnerHealth hub focused on accessibility that provides patients with benefits and access to treatments. Partner offering differentiated conditions for patients.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Prati-Donaduzzi: One of Brazil's largest generic pharmaceutical manufacturers, Prati-Donaduzzi has entered the medical cannabis market with ANVISA-approved cannabis products sold through Brazilian pharmacies. Most directly comparable to Ease Labs in business model, regulatory positioning, and target market.
• Entourage Phytotech (Nunature): Brazilian cannabis company focused on research, development, and commercialization of cannabinoid-based products for medical use in Brazil. Competes in the same prescription cannabis segment with similar ANVISA-regulated pharmacy distribution.
• Vale Verde Pharma: Brazilian pharmaceutical company specializing in medical cannabis products, producing cannabis-based medicines for the Brazilian market. Direct competitor with similar regulatory pathway and product portfolio focus.
• Cannabis Bioss: Brazilian cannabis company offering cannabinoid-based pharmaceutical products through regulated pharmacy channels. Competes directly in the Brazilian medical cannabis market with similar product positioning and distribution approach.

Emerging players

• Tilray Brands: Global cannabis leader with pharmaceutical-grade operations and international distribution, including presence in Latin America. Comparable in product category (cannabis-based therapeutics) and pharmaceutical positioning, though operating at much larger scale.
• Aurora Cannabis: Canadian licensed producer of medical cannabis products with international operations including Europe and emerging LatAm markets. Comparable in pharmaceutical-grade production and medical channel focus, though at significantly larger scale.
• Canopy Growth Corporation: Global cannabis company with pharmaceutical-grade medical cannabis products marketed internationally. Comparable in regulated pharmaceutical positioning and physician-channel distribution, though broader product portfolio and geographic scope.
• Cronos Group: Canadian cannabis company with international medical cannabis operations including Latin America presence. Comparable in regulatory-driven pharmaceutical model and medical channel focus.

Broad incumbents

• Eurofarma Laboratórios: Major Brazilian pharmaceutical company with diverse product portfolio including potential cannabis-related initiatives. Comparable as a broad pharmaceutical incumbent in the Brazilian market with overlapping distribution channels through pharmacies.
• Hypera Pharma: Largest Brazilian pharmaceutical company by market cap, with diversified OTC and prescription portfolio. Comparable in broad Brazilian pharmaceutical operations and pharmacy distribution, though not cannabis-focused.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/easelabs
• Facebookfacebook.com/easelabs

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ease Labs International